{
    "organizations": [],
    "uuid": "0cb26f514e32d7339e0f202580f5839dfab8ce4a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-actobio-therapeutics-greenlighted/brief-actobio-therapeutics-greenlighted-by-fda-to-commence-a-phase-ib-iia-trial-with-ag019-idUSASC09U8G",
    "ord_in_thread": 0,
    "title": "BRIEF-Actobio Therapeutics Greenlighted By FDA To Commence A Phase Ib/Iia Trial With AG019",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29, 2018 / 1:31 PM / in 7 minutes BRIEF-Actobio Therapeutics Greenlighted By FDA To Commence A Phase Ib/Iia Trial With AG019 Reuters Staff 1 Min Read \nMarch 29 (Reuters) - Intrexon Corp: \n* ACTOBIO THERAPEUTICS GREENLIGHTED BY FDA TO COMMENCE A PHASE IB/IIA TRIAL WITH AG019 FOR THE TREATMENT OF EARLY ONSET TYPE 1 DIABETES \n* ACTOBIO THERAPEUTICS SAYS “SOON WILL START CLINICAL TRIALS” WITH AG019 “IN ASSOCIATION WITH SPECIALIZED INSTITUTES IN EUROPE AND NORTH AMERICA” Source text for Eikon: Further company coverage:",
    "published": "2018-03-29T16:30:00.000+03:00",
    "crawled": "2018-03-29T16:52:57.073+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "therapeutic",
        "greenlighted",
        "fda",
        "commence",
        "phase",
        "trial",
        "ag019",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "intrexon",
        "corp",
        "actobio",
        "therapeutic",
        "greenlighted",
        "fda",
        "commence",
        "phase",
        "trial",
        "ag019",
        "treatment",
        "early",
        "onset",
        "type",
        "diabetes",
        "actobio",
        "therapeutic",
        "say",
        "soon",
        "start",
        "clinical",
        "trial",
        "ag019",
        "association",
        "specialized",
        "institute",
        "europe",
        "north",
        "america",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}